Fe-Catalyzed Reductive Couplings of Terminal (Hetero)Aryl Alkenes and Alkyl Halides under Aqueous Micellar Conditions
作者:Haobo Pang、Ye Wang、Fabrice Gallou、Bruce H. Lipshutz
DOI:10.1021/jacs.9b04510
日期:2019.10.30
aromatic or heteroaromatic and an alkyl bromide or iodide leads, in the presence of Zn and a catalytic amount of an Fe(II) salt, to a net reductive coupling. The new C-C bond is regiospecifically formed at rt at the -site of the al-kene. The coupling only occurs in an aqueous micellar medium, where an atypical carbanionic, as opposed to radical, process is likely, supported by several control experiments
在Zn和催化量的Fe(II)盐的存在下,乙烯基取代的芳族或杂芳族和烷基溴或碘的组合导致净还原偶联。新的 CC 键在 rt 在烯烃的 位点区域特异性地形成。偶联仅发生在水性胶束介质中,其中可能是非典型的碳负离子过程,而不是自由基过程,这得到了几个控制实验的支持。提出了一种基于这些数据的机制。
[EN] ANTIFUNGAL COMPOUND PROCESS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE COMPOSÉ ANTIFONGIQUE
申请人:VIAMET PHARMACEUTICALS INC
公开号:WO2015143137A1
公开(公告)日:2015-09-24
The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 or la and substituted derivatives thereof.
2-Pyridylquinolone
antimalarials with improved antimalarial activity and physicochemical properties
作者:Sitthivut Charoensutthivarakul、W. David Hong、Suet C. Leung、Peter D. Gibbons、Paul T. P. Bedingfield、Gemma L. Nixon、Alexandre S. Lawrenson、Neil G. Berry、Stephen A. Ward、Giancarlo A. Biagini、Paul M. O'Neill
DOI:10.1039/c5md00062a
日期:——
2-Pyridylquinolones with improved solubility, an improved metabolic stability profile, reduced off-target toxicity and 12 nM Plasmodium falciparum antimalarial activity are described.
The instant invention describes compounds of Formula I having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
本发明描述了具有金属酶调节活性的I型化合物,并提供了治疗由这些金属酶介导的疾病、疾病或症状的方法。
Metalloenzyme inhibitor compounds as fungicides
申请人:Dow AgroSciences LLC
公开号:US10167300B2
公开(公告)日:2019-01-01
The instant invention describes compounds of Formula I having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.